Novel Dual Action Treatment of Acute Cardiovascular Syndrome with Craig Fraser Windtree Therapeutics

Published: Oct. 5, 2020, 5:46 p.m.

Craig Fraser, CEO and President, Windtree Therapeutics talks about acute heart failure, the number one reason for hospitalization in people over 65 and the fact that there has been little innovation in trying to improve cardiac function. Developing a novel dual action drug called istaroxime, Windtree is addressing both parts of the cycles of the heart - increasing blood pressure and also lowering the heart rate. After using a diuretic, administration of ista is producing positive data for better function of the heart.

@windtreetx #AHF #HeartFailure #cardiovascular

Windtreetx.com

Download the transcript here

Windtree